Status:
COMPLETED
Chloroquine for Treatment of Glioblastoma Multiforme
Lead Sponsor:
National Institute of Neurology and Neurosurgery, Mexico
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Chloroquine is a strong lysosomotropic and DNA-intercalating agent in experimental studies (Neurosurgical Focus 14(2): February, 2003) and an open-label clinical trial the investigators have demonstra...
Detailed Description
ANTECEDENTS: We have shown experimentally a significant adjuvant effect of quinacrine (an analog of chloroquine) on cultured malignant glial cells and C6 implanted malignant glioma in Wistar rats. Whe...
Eligibility Criteria
Inclusion
- Tumor restricted to one hemisphere of the brain
- Karnofsky scale \>7
- Histologically confirmed GBM in first or second recurrence or relapse
- Adequate hematologic, hepatic and renal function
- Karnofsky performance status score ≥ 70%
- Life expectancy ≥ 16 weeks
Exclusion
- Gastrointestinal dysfunction
- Compromised cardiac function
- Concurrent severe and /or uncontrolled medical conditions
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00224978
Start Date
January 1 2005
End Date
August 1 2005
Last Update
November 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Neurology and Neurosurgery
Mexico City, Mexico, 14269